Status:
COMPLETED
Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines...
Eligibility Criteria
Inclusion
- Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines
Exclusion
- High liver enzymes
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
1120 Patients enrolled
Trial Details
Trial ID
NCT00174304
Start Date
October 1 2004
End Date
September 1 2006
Last Update
January 27 2021
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Salzburg, Austria, A-5020
2
Pfizer Investigational Site
Sankt Pölten, Austria, A-3100
3
Pfizer Investigational Site
Vienna, Austria, A-1090
4
Pfizer Investigational Site
Wels, Austria, A-4600